^{Photo: Logos Press}

Zealand Pharma Under Pressure After Historic Share Price Collapse

Danish biotechnology company Zealand Pharma has endured one of the most challenging periods in its history, with investors reassessing the company's position in the rapidly expanding obesity treatment market. Following disappointing clinical updates from its obesity drug pipeline, the company's shares experienced their two steepest single-day declines since listing on the stock exchange in 2010.

Despite the sharp selloff, analysts and institutional investors have not abandoned the company. Instead, attention is increasingly shifting toward Zealand’s next-generation obesity candidate, petrelintide, which many believe could become the company's most valuable long-term asset.

The recent volatility highlights how competitive and demanding the weight loss drug market has become, where investors are no longer focused solely on weight-loss percentages. Factors such as patient adherence, side effects, convenience, and long-term tolerability are now playing an equally important role in determining commercial success.

Survodutide Data Triggers Major Reassessment

Investor confidence took a significant hit after detailed clinical trial results for survodutide, a drug licensed to privately held pharmaceutical giant Boehringer Ingelheim, revealed substantially higher patient dropout rates than expected.

While the treatment successfully achieved its primary objective and delivered an average weight reduction of 16.6%, nearly one in five patients (19%) discontinued treatment because of adverse side effects.

The market reaction was swift.

Zealand Pharma shares plunged approximately 23% following the data release, as analysts questioned whether the drug could effectively compete against established market leaders.

The concern was not the efficacy of the drug itself. A weight-loss result above 15% remains highly competitive within the obesity treatment landscape. Instead, the issue centered on tolerability.

If patients cannot comfortably remain on treatment, commercial adoption becomes significantly more difficult regardless of effectiveness.

For comparison, leading obesity drugs such as Wegovy and Zepbound have demonstrated placebo-adjusted discontinuation rates closer to 4%, making survodutide's nearly 19% rate a substantial disadvantage.

As a result, several investment firms sharply reduced their revenue expectations for the drug.

Another Blow Follows Earlier Petrelintide Disappointment

The survodutide setback arrived only months after another major disappointment.

In March, Zealand Pharma shares fell roughly 36% after mid-stage trial data showed petrelintide producing weight loss of just under 11%, below many investor expectations.

Although management emphasized that the study was not optimized to maximize weight reduction and that the drug's development program remains on track, investors reacted negatively.

The combination of the March decline and the recent June selloff erased billions of kroner from Zealand Pharma's market value and forced analysts to revisit their long-term forecasts.

Even after recovering part of those losses, the stock remains down approximately 38% year-to-date, reflecting continued uncertainty surrounding the company's obesity strategy.

Analysts Slash Forecasts but Maintain Long-Term Confidence

Following the survodutide update, analysts at UBS significantly reduced their valuation assumptions.

The bank lowered its price target on Zealand Pharma shares from 730 Danish kroner to 540 Danish kroner, while cutting projected peak sales for survodutide by nearly 80%.

According to analysts, the tolerability profile now appears likely to limit the drug's widespread use in obesity treatment.

However, UBS maintained a Buy rating on the stock, highlighting that petrelintide remains the most important asset in Zealand's portfolio.

This distinction is critical.

While survodutide was previously viewed as a major growth engine, many investors are now assigning greater importance to petrelintide's future commercial potential.

Why Petrelintide Is Becoming the Centerpiece of Zealand’s Strategy

The obesity treatment industry is evolving rapidly.

For years, drug developers competed primarily on one metric: how much weight patients could lose.

Today, the discussion has expanded.

Doctors, researchers, and investors increasingly recognize that patients need therapies they can tolerate for years rather than months. A slightly lower weight-loss outcome may be acceptable if patients experience fewer side effects and remain on treatment longer.

This shift is creating significant interest in a newer category of medicines known as amylin-based therapies.

Petrelintide belongs to this emerging class.

Unlike GLP-1 drugs, which mimic hormones produced in the gut, amylin therapies replicate a naturally occurring hormone produced in the pancreas that helps regulate appetite, food intake, and blood sugar levels.

Industry experts increasingly view amylin drugs as a potential complement—or even alternative—to current GLP-1 therapies.

The Growing Appeal of “Better Tolerability”

A major theme emerging from recent obesity and diabetes conferences is the search for treatments that balance meaningful weight loss with minimal side effects.

Current blockbuster therapies have achieved remarkable results, but many patients struggle with gastrointestinal complications, nausea, vomiting, and treatment discontinuation.

This has created demand for therapies that may not necessarily deliver the highest weight-loss percentages but offer a substantially better patient experience.

Petrelintide appears positioned within this category.

Management believes the drug occupies a unique space between strong double-digit weight loss and near-placebo levels of tolerability.

If future studies confirm that profile, the therapy could become particularly attractive for long-term weight management and maintenance after patients complete treatment with traditional GLP-1 medications.

The commercial opportunity is significant because obesity affects hundreds of millions of people globally, and healthcare systems increasingly recognize obesity as a chronic disease requiring long-term management.

Competition Is Intensifying Across the Industry

While petrelintide offers promise, Zealand Pharma faces formidable competition.

Industry leaders Eli Lilly and Novo Nordisk continue to dominate the obesity market, generating billions of dollars in annual revenue from their respective weight-loss franchises.

At recent scientific conferences, Eli Lilly unveiled new data for retatrutide, an experimental "triple-hormone" therapy that combines three separate metabolic pathways to maximize weight reduction.

The results impressed many analysts, with some describing retatrutide as potentially the most effective obesity therapy currently in development.

Importantly, long-term data suggested patients continued losing weight beyond two years of treatment without reaching a clear efficacy plateau.

Against that backdrop, Zealand's clinical results faced even greater scrutiny.

Investors were not only evaluating survodutide on its own merits but also comparing it against increasingly powerful next-generation competitors.

Roche Partnership Adds Strategic Value

One factor supporting investor confidence is Zealand Pharma's partnership with Swiss pharmaceutical giant Roche.

The collaboration provides substantial financial resources, development expertise, and commercial infrastructure that could accelerate petrelintide's path to market.

The company is expected to begin pivotal late-stage trials for petrelintide during the second half of the year.

In addition, upcoming mid-stage diabetes trial results could provide further evidence regarding the drug's effectiveness in patients who traditionally find weight loss more challenging.

Positive outcomes from either program could serve as important catalysts for the stock.

Survodutide May Still Have a Future Beyond Obesity

Although enthusiasm for survodutide as a pure obesity treatment has declined, analysts believe the drug may still play an important role in another rapidly growing market.

Several experts see potential for the therapy in treating metabolic dysfunction-associated steatohepatitis (MASH), commonly known as fatty liver disease.

This condition affects millions of patients worldwide and represents a major unmet medical need.

If future studies demonstrate meaningful liver-related benefits, survodutide could still generate substantial commercial value despite concerns surrounding its obesity profile.

As a result, investors are increasingly viewing the drug through the lens of liver disease rather than weight management alone.

The Road Ahead May Be Long

Despite continued optimism around petrelintide, most analysts believe a major turning point for Zealand Pharma may not arrive immediately.

Several research firms suggest the company's next significant valuation inflection point could occur in 2027, when larger clinical datasets become available and investors gain a clearer picture of petrelintide's competitive positioning.

Until then, the stock is likely to remain sensitive to clinical updates, industry developments, and competitive data releases.

Bottom Line

Zealand Pharma finds itself at a critical crossroads.

The company's obesity ambitions have been challenged by disappointing survodutide tolerability data and investor concerns surrounding petrelintide's early efficacy results. These setbacks have triggered historic share-price declines and forced analysts to lower expectations.

However, the broader investment thesis remains intact for many observers.

The growing industry focus on tolerability, patient retention, and long-term treatment adherence is creating a favorable environment for amylin-based therapies such as petrelintide. Combined with support from Roche and upcoming late-stage studies, Zealand still possesses meaningful opportunities to regain investor confidence.

For now, survodutide appears to be transitioning into a liver-disease-focused asset, while petrelintide increasingly carries the responsibility of defining Zealand Pharma's future in the global obesity market.